1 active not recruiting, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Neurogene Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gene Therapy Study for Children With CLN5 Batten Disease NGN-101 - Neuronal Ceroid Lipofuscinosis CLN5 | Phase 1 / Phase 2 | Active not recruiting | Neurogene Inc. | 6 | 2022-01-31 | 2024-08-12 |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer NL-201, Pembrolizumab Injection [Keytruda] - Solid Tumor, Advanced Solid Tumor | Phase 1 | Completed | Neurogene Inc. | 59 | 2021-04-26 | 2024-10-01 |
Neoplasms (1) · Neuronal Ceroid-Lipofuscinoses (1)
pembrolizumab (1)
United States (2) · Australia (1) · Canada (1) · United Kingdom (1)
Albiruni A Razak (1) · Effie Albanis, MD (1)